Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care

Tarsus closes the Alkeus deal, adding late-stage ALK-001 for Stargardt disease and multiple FDA designations to its eye care pipeline.

Rhea-AI Summary

Tarsus Pharmaceuticals (TARS) has completed its previously announced acquisition of Alkeus Pharmaceuticals, a privately held biotechnology company focused on retinal diseases.

With the closing, Tarsus gains worldwide rights to gildeuretinol (ALK-001), a differentiated, late-stage, oral investigational medicine designed to reduce toxic dimer accumulation while preserving the normal visual cycle in Stargardt disease. Tarsus states that ALK-001 could be a potential blockbuster in one of the largest inherited retinal diseases and is highly complementary to its eye care focus.

ALK-001 has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. FDA for Stargardt disease and is being evaluated in the global NORTHSTAR Phase 3 trial, with topline data anticipated in 2029. The transaction closed after satisfaction of customary conditions under the definitive merger agreement.

Positive

• Acquisition of Alkeus completed, adding a retinal disease-focused biotech and its programs to Tarsus’ portfolio.
• Worldwide rights to ALK-001, a late-stage oral investigational therapy targeting Stargardt disease biology.
• ALK-001 holds four FDA designations for Stargardt disease: Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease.
• ALK-001 is in a global Phase 3 NORTHSTAR trial, with topline data anticipated in 2029, expanding Tarsus’ late-stage pipeline.

Negative

• None.

Market Context

TARS's prior Alkeus acquisition announcement was followed by a 6.59% 24-hour move. That platform com...

Analysis

TARS's prior Alkeus acquisition announcement was followed by a 6.59% 24-hour move. That platform comparison frames completion as a progression event; clinical execution remains a risk, while recent insider activity was net selling.

Key Figures

Clinical Phase: Phase 3 Topline Data Timing: 2029 Acquisition Announcement Date: August 6, 2026 +1 more

4 metrics

Clinical Phase Phase 3 ALK-001 for Stargardt disease

Topline Data Timing 2029 NORTHSTAR Phase 3 trial

Acquisition Announcement Date August 6, 2026 Previously announced Alkeus acquisition

Acquisition Completion Date September 04, 2026 Alkeus acquisition completion announcement

Previous Acquisition Reports

2 past events · Latest: Aug 06 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 06	Alkeus acquisition agreement	Positive	+6.6%	Agreement added ALK-001 and included upfront consideration plus potential milestones.
Jul 08	iRenix acquisition agreement	Positive	-5.3%	Agreement added IRX-101 and late-stage ocular antiseptic development rights.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tarsus showed mixed reactions to acquisition news, with one positive alignment and one negative divergence.

Key Terms

phase 3, breakthrough therapy, orphan drug, fast track, +1 more

5 terms

phase 3 medical

"a differentiated Phase 3 oral investigational medicine"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

breakthrough therapy regulatory

"has received Breakthrough Therapy, Orphan Drug, Fast Track"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

orphan drug regulatory

"received Breakthrough Therapy, Orphan Drug, Fast Track"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"Orphan Drug, Fast Track and Rare Pediatric Disease designations"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

rare pediatric disease regulatory

"Fast Track and Rare Pediatric Disease designations"

A rare pediatric disease is a serious medical condition that primarily affects children and occurs so infrequently that only a small number of patients exist. Investors care because treatments for such conditions often get special regulatory incentives—think of government fast lanes and rewards for developers—making smaller markets potentially profitable due to pricing power, shorter development timelines, and reduced competition, much like a niche product that receives government-backed advantages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a potentially blinding disease with no FDA-approved therapy

Strengthens Tarsus’ differentiated pipeline and leadership in eye care

IRVINE, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that it has completed its previously announced acquisition of Alkeus Pharmaceuticals, Inc., a privately held retinal disease-focused biotechnology company.

With the completion of the acquisition, Tarsus adds worldwide rights to ALK-001, a new, investigational, late-stage molecular entity designed to reduce the accumulation of toxic dimers while preserving the normal visual cycle. Tarsus believes ALK-001 represents a potential blockbuster opportunity in one of the largest inherited retinal diseases. ALK-001 has received Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for Stargardt disease and is currently being evaluated in the global NORTHSTAR Phase 3 trial, with topline data anticipated in 2029.

“Completing the Alkeus acquisition marks an important step forward in our vision to build a leading eye care company,” said Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “ALK-001 is highly complementary to our core strengths and has the potential to become a foundational medicine for people living with Stargardt disease, a potentially blinding disease with no FDA-approved treatment. With the transaction complete, our focus is on advancing the NORTHSTAR trial and realizing the full potential of this important clinical-stage program.”

The acquisition of Alkeus, announced on August 6, 2026, closed following the satisfaction of the customary closing conditions set forth in the definitive merger agreement.

About Gildeuretinol Acetate (ALK-001)
Gildeuretinol acetate (ALK-001) is an investigational small molecule with a once-daily oral formulation targeting toxic vitamin A dimerization in the retina and has demonstrated a promising tolerability and efficacy profile across more than 400 individuals studied.

About Stargardt Disease
Stargardt disease is a rare, inherited and progressive retinal disease that often begins in childhood or early adulthood. It damages the macula, the central portion of the retina responsible for detailed vision, and can progressively affect patients' ability to read, recognize faces, drive and live independently. Stargardt disease is estimated to affect as many as 86,000 people in the United States, more than 36,000 of whom have been clinically diagnosed, and there are currently no FDA-approved therapies.

About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY^® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ocular rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, both of which are in Phase 2, IRX-101 for potential use as an ocular antiseptic, and gildeuretinol for the potential treatment of Stargardt disease.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include statements regarding the anticipated benefits of the acquisition of Alkeus and the integration of Alkeus into Tarsus; the potential mechanisms of action, therapeutic benefits of and potential market size for gildeuretinol; anticipated regulatory and development milestones; the timing for topline data for, and results of, Tarsus' clinical studies including the NORTHSTAR trial; and the quotations of Tarsus' management. The words, without limitation, "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "on track," or "would," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks that the anticipated benefits of the acquisition are not realized. Further risks and uncertainties are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus' Form 10-K for the year ended December 31, 2025 filed with the SEC on February 23, 2026, and its most recent Form 10-Q filed with the SEC on August 6, 2026, copies of which are posted on its website and are available from Tarsus without charge. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus' management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Media Contact:
Adrienne Kemp
Vice President, Corporate Communications
(949) 922-0801
akemp@tarsusrx.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

What acquisition did Tarsus Pharmaceuticals (TARS) complete involving Alkeus Pharmaceuticals?

Tarsus Pharmaceuticals completed its previously announced acquisition of Alkeus Pharmaceuticals, a privately held biotechnology company focused on retinal diseases, adding Alkeus’ programs and assets to Tarsus’ eye care portfolio after satisfying customary closing conditions in the definitive merger agreement.

What is ALK-001 (gildeuretinol) that Tarsus (TARS) gained through the Alkeus acquisition?

ALK-001 (gildeuretinol) is a differentiated, oral, Phase 3 investigational medicine designed to reduce the accumulation of toxic dimers while preserving the normal visual cycle in Stargardt disease, a potentially blinding inherited retinal disease with no FDA-approved therapy.

Which FDA designations has ALK-001 for Stargardt disease after the Tarsus (TARS) acquisition?

ALK-001 has received four U.S. FDA designations for Stargardt disease: Breakthrough Therapy, Orphan Drug, Fast Track and Rare Pediatric Disease. These regulatory designations were obtained before the acquisition and now support the program within Tarsus’ eye care pipeline.

What clinical stage is ALK-001 in and when is Phase 3 data expected for Tarsus (TARS)?

ALK-001 is a late-stage, Phase 3 investigational therapy being evaluated in the global NORTHSTAR trial. Tarsus indicates that topline data from this Phase 3 study are anticipated in 2029, guiding the future development path for Stargardt disease treatment.

How does the Alkeus acquisition affect Tarsus Pharmaceuticals’ (TARS) eye care pipeline?

The acquisition strengthens Tarsus’ eye care pipeline by adding worldwide rights to ALK-001, a late-stage oral candidate with multiple FDA designations. The company describes ALK-001 as highly complementary to its core strengths and a potential foundational medicine for Stargardt disease.

When was the Alkeus acquisition by Tarsus (TARS) first announced and when did it close?

The acquisition of Alkeus by Tarsus was initially announced on August 6, 2026. It closed after the satisfaction of the customary closing conditions set forth in the definitive merger agreement, with completion reported on September 4, 2026.